Conquering oncogenic KRAS and its bypass mechanisms
Pingping Hou1,2,3,4, Y Alan Wang5
1Center for Cell Signaling, Rutgers New Jersey Medical School, Newark, New Jersey 07103, USA.
Theranostics
|August 15, 2022
Summary
Targeting KRAS signaling in cancer shows promise, but resistance mechanisms limit effectiveness. Understanding these bypass pathways is key to developing effective combination therapies for KRAS-driven cancers.
Area of Science:
- Oncology
- Molecular Biology
- Drug Development
Background:
- Aberrant KRAS signaling is a hallmark of many cancers, driving the development of targeted therapies.
- Novel small molecule drugs targeting KRAS and its effectors show preclinical and clinical promise.
- Cancer's inherent genetic and biological plasticity leads to resistance mechanisms against targeted therapies.
Purpose of the Study:
- To review the mechanisms of resistance to KRAS-targeted therapies.
- To highlight the importance of understanding resistance for improving clinical outcomes.
- To inform the development of combination strategies against KRAS-driven cancers.
Main Methods:
- Literature review of preclinical and clinical studies on KRAS-targeted therapies.
- Analysis of identified resistance mechanisms in various cancer types.
- Synthesis of knowledge to propose combination strategies.
Main Results:
- KRAS-targeted drugs demonstrate significant activity but are often limited by acquired resistance.
- Diverse resistance mechanisms, including bypass signaling pathways, are frequently observed.
- Understanding these resistance mechanisms is crucial for overcoming therapeutic limitations.
Conclusions:
- Targeted inhibition of KRAS is a viable strategy, but resistance remains a significant challenge.
- Combination therapies that address both KRAS dependency and bypass mechanisms are needed.
- Further research into resistance pathways will guide the next generation of cancer treatments.
Related Concept Videos
02:38The Ras Gene
6.4K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.4K
01:33Cancer-Critical Genes I: Proto-oncogenes
9.1K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.1K
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
01:24Small GTPases - Ras and Rho
4.2K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
4.2K
02:38Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
02:53Adaptive Mechanisms in Cancer Cells
5.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K